EyePoint Pharmaceuticals reports mixed results for DURAVYU in Phase 2 diabetic retinopathy trial
EyePoint Pharmaceuticals, Inc., committed to innovative therapeutics for serious retinal diseases, today disclosed the top-line results of the Phase 2 PAVIA clinical trial for DURAVYU (previously known as EYP-1901). This trial evaluated DURAVYU in patients with non-proliferative diabetic retinopathy (NPDR), revealing that while the treatment exhibits a biologic effect and a favorable safety profile, it […]